黑料不打烊

Global Multiple Myeloma Market Trends and Insights

Rising Prevalence of Multiple Myeloma

Incident cases continue to climb as diagnostic sensitivity improves and populations age. The International Agency for Research on Cancer estimated 176,000 new diagnoses worldwide in 2024 and projects 210,000 annually by 2030.^{[1]International Agency for Research on Cancer, 鈥淐ancer Today,鈥� gco.iarc.fr} A median diagnosis age near 69 ensures that the post-war baby-boom cohort sustains patient inflows, while enhanced imaging tools detect smoldering disease earlier, extending treatment sequences across more therapy lines. Ethnic disparities also shape demand, with individuals of African descent experiencing double the incidence of their European-descent counterparts, prompting targeted U.S. screening initiatives. As median survival now exceeds 8 years, each additional patient contributes durable revenue streams despite per-patient costs plateauing.

Launch Pace of Next-Gen Immunotherapies

Between January 2024 and December 2025, regulators cleared three bispecific T-cell engagers and two CAR-T constructs, compressing clinic-to-market timelines to under 9 months.^{[2]U.S. Food and Drug Administration, 鈥淭eclistamab Approval,鈥� fda.gov} Off-the-shelf agents such as teclistamab generated USD 890 million in 2025 sales as community oncologists administered subcutaneous injections without leukapheresis infrastructure. Supplemental filings to move these drugs into second-line use could divert USD 2 billion annually from triplet regimens if ongoing trials confirm non-inferiority. Competitive differentiation is shifting toward safety metrics, such as cytokine release syndrome incidence, as efficacy rates converge.

Rapid Aging of High-Income Populations

Persons aged 65 and older will account for 21% of OECD citizens by 2030, up from 17% in 2020. Because the risk of multiple myeloma doubles every decade after age 50, case counts rise even if age-adjusted incidence stabilizes. Geriatric guidelines now mandate frailty assessments before CAR-T infusion, given the 40% higher rate of grade-3 cytokine release syndrome in patients. Demand for subcutaneous and oral formulations that minimize clinic visits is therefore climbing, evidenced by daratumumab-hyaluronidase securing 55% of new anti-CD38 prescriptions in the United States during H2 2025.

Favorable Reimbursement in United States and Europe

Medicare鈥檚 2025 National Coverage Determination removed evidence-development requirements for CAR-T, opening billing access for 400 additional hospitals.^{[3]Centers for Medicare & Medicaid Services, 鈥淣ational Coverage Determination for CAR-T,鈥� cms.gov} In Europe, Germany鈥檚 IQWiG issued positive assessments for teclistamab at EUR 185,000 per patient, securing rapid reimbursement. Managed-access agreements in the UK and early-access authorizations in France shaved nine months off time-to-market, illustrating payer willingness to absorb high upfront costs in exchange for durable remissions.

High Price of Novel Therapies

CAR-T infusions cost USD 475,000 in the United States, and bispecific antibodies cost USD 23,000 per month, placing curative-intent care beyond reach for 60% of the world, lacking catastrophic coverage. India鈥檚 median household income of USD 2,400 renders an annual isatuximab course of USD 280,000 unaffordable without subsidy, while China negotiated a 70% discount on domestic CAR-T products to bring costs below USD 150,000. Outcomes-based deals, such as Novartis refunding 50% of the price of tisagenlecleucel for non-responders, are emerging but require sophisticated data infrastructure.

Drug-Resistance & Severe Adverse Events

About 30% of anti-BCMA CAR-T recipients relapse within 18 months due to antigen escape, and grade-3 cytokine release syndrome affects 8% of cellular-therapy patients, necessitating ICU-level care. The FDA added a boxed neurotoxicity warning to teclistamab in February 2025 after fatal cerebral edema cases, temporarily dampening uptake. Persistent B-cell aplasia drives infection rates above 40%, adding USD 30,000 in IV immunoglobulin costs per patient-year.

Segment Analysis

By Drug Class: Cellular Therapies Outpace Legacy Platforms

Immunomodulators accounted for 34.82% of 2025 revenue, yet CAR-T and cell-based products are forecast to grow at a 10.06% CAGR, underscoring the pivot toward durable remissions in earlier lines. Anti-BCMA constructs are replacing proteasome inhibitors in third-line care, as belantamab mafodotin鈥檚 revised dosing halves the incidence of corneal toxicity. The multiple myeloma market size for CAR-T is presently limited by the apheresis bottleneck, yet planned capacity additions could unlock new demand curves beyond 2027. Allogeneic off-the-shelf candidates like UCART19 achieved 45% complete remission rates in Phase I, hinting at future disruption once durability concerns are resolved.

Manufacturing ceilings constrain supply, but investment momentum is strong. Legend Biotech鈥檚 upcoming plant should lower per-dose costs by 35%, while FDA draft rules on closed-system bioreactors may let community hospitals capture production economics locally. Should point-of-care models prevail, the multiple myeloma market could double cellular-therapy penetration by the end of the forecast horizon, diverting revenue from oral immunomodulators that today dominate maintenance settings.

Note: Segment shares of all individual segments available upon report purchase

By Therapy Type: Quadruplet Regimens Redefine Standards

Combination protocols accounted for 61.27% of 2025 prescriptions and will grow at a 9.63% CAGR, driven by quadruplets pairing anti-CD38 monoclonals with lenalidomide-bortezomib backbones. The MAIA trial reported a 44% reduction in progression risk, prompting NCCN to elevate the triplet to preferred frontline care. Monotherapy remains material in maintenance, where single-agent lenalidomide offers convenience for transplant recipients achieving MRD negativity. The multiple myeloma market share for quadruplets is poised to climb once bispecific antibodies are integrated into second-line cocktail studies, with results expected in 2027.

Maintenance monotherapy enjoys an identical 9.63% CAGR to combination therapy because ongoing MRD-guided de-escalation allows oncologists to extend treatment to capture survival gains. Ixazomib鈥檚 26-month median progression-free survival in maintenance secured FDA approval in 2024, and real-world European data show 70% two-year progression-free survival with single-agent subcutaneous daratumumab. Sequencing strategy, more than regimen intensity, is now the key determinant of long-term outcomes.

By Route of Administration: Subcutaneous Formulations Gain Share

Intravenous dosing accounted for 49.71% of 2025 volume, yet subcutaneous delivery is advancing at an 8.86% CAGR as hyaluronidase-enabled formulations trim chair time to 5 minutes. CMS parity reimbursement erased the financial penalty for faster injections, helping subcutaneous daratumumab claim 60% of new U.S. prescriptions within a year of approval. Oral agents, while convenient, still require monthly labs, posing adherence hurdles for elderly cohorts.

The subcutaneous surge alters site-of-care economics, allowing ambulatory clinics to treat 40% more patients per suite without adding chairs. Oral regimens dominate maintenance therapy thanks to once-daily dosing, but myelosuppression-driven dose reductions in 40% of seniors limit universal uptake. Intravenous routes retain primacy for conditioning and step-up dosing because 48-hour observation is mandatory during CRS-risk windows.

Note: Segment shares of all individual segments available upon report purchase

By Distribution Channel: Specialty Networks Capture Oral Volume

Hospital pharmacies dispensed 68.23% of the 2025 doses for inpatient CAR-T infusions and CRS management. Online specialty pharmacies are growing fastest, with a 10.41% CAGR, as payers mandate mail-order fulfillment for oral agents exceeding USD 10,000 monthly. UnitedHealthcare, Cigna, and Humana now require specialty-network use, helping Accredo fill 120,000 lenalidomide scripts in 2025 while its digital platform flagged 8,000 adherence lapses for real-time outreach.

Retail pharmacies shrink as rebate-rich specialty channels underprice them; Walgreens exited oncology specialty services in 2025. Hospital channels will continue to dominate high-margin cellular therapies, whereas specialty networks will double oral-agent share by 2031, bifurcating supply between inpatient high-complexity care and at-home chronic therapy.

Geography Analysis

North America generated 44.08% of global revenue in 2025, buoyed by Medicare coverage expansions and a network of 280 certified CAR-T centers. Four novel therapies cleared FDA review in 2025, cutting launch lag to nine months, while Canada鈥檚 45% price cut for Carvykti and Mexico鈥檚 inclusion of subcutaneous daratumumab in public formularies broadened regional access. 

Asia-Pacific will post the fastest regional growth rate at 12.27% CAGR. China approved Carvykti at CNY 1.2 million, immediately adding it to the national reimbursement list with 70% coverage, thereby making cellular therapy accessible to 15,000 patients per year. Japan reimbursed teclistamab at JPY 25 million per patient, aligning with cost-effectiveness thresholds, while Australia reduced patient co-pays for isatuximab to AUD 42 per fill. India slashed lenalidomide caps, yet rural penetration remains low, underscoring the urban鈥搑ural care divide in the multiple myeloma industry.

Germany and the UK granted positive health-technology assessments for teclistamab and Carvykti, embedding managed-access agreements that tie payments to five-year overall survival targets. France鈥檚 early-access route shortened time-to-reimbursement by nine months, while Italy鈥檚 essential-medicines list now includes subcutaneous daratumumab. Sub-Saharan Africa and most of the Middle East lag due to funding deficits, save for the UAE, which approved government reimbursement for daratumumab in 2025, signaling incremental progress in access equity.